Načítá se...
SUN-173 Nivolumab-Induced Fulminant Autoimmune Diabetes Presenting as Diabetic Ketoacidosis in a Patient with Melanoma
Background: Anti PD-1 antibody immunotherapies like nivolumab and pembrolizumab are newer agents used in the treatment of melanoma and multiple other types of advanced cancers. Immune-mediated endocrinopathies triggered by these drugs are increasingly reported in literature and encountered by endocr...
Uloženo v:
| Vydáno v: | J Endocr Soc |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Endocrine Society
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553338/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-173 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|